Overview

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Status:
Completed

Trial end date:
2019-01-23

Target enrollment:

Participant gender:

Summary

The purpose of this study is to examine the safety and efficacy of Ibrutinib administered in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Phase:

Phase 3

Details

Lead Sponsor:

Janssen Research & Development, LLC

Collaborator:

Pharmacyclics LLC.

Treatments:

Bendamustine Hydrochloride
Rituximab